SECsense Logo

AstraZeneca PLC Form 6-K Report: Insider Share Sale Notification August 2025

$AZN
Form 6-K
Filed on: 2025-08-18
Source
AstraZeneca PLC Form 6-K Report: Insider Share Sale Notification August 2025

Here are the key insights and information extracted from the provided section of the financial report:

  1. Report Type and Filing Date: The document is a Form 6-K filed with the SEC on August 18, 2025, for the month of August 2025.
  2. Company Information:
  • Company Name: AstraZeneca PLC
  • Headquarters: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom.
  • SEC File Number: 001-11960
  1. Director/PDMR Shareholding:
  • The report notifies about a transaction by a person discharging managerial responsibilities (PDMR), specifically Aradhana Sarin, the Executive Director and Chief Financial Officer (CFO) of AstraZeneca.
  1. Transaction Details:
  • Date of Transaction: August 14, 2025
  • Nature of Transaction: Sale of ordinary shares.
  • Quantity Sold: 9,563 shares.
  • Price per Share: £115.117.
  1. Compliance: The transaction was made in accordance with the requirements of the EU Market Abuse Regulation, which is part of UK law.
  2. Initial Notification: This report serves as the initial notification of the transaction.
  3. Details of the Financial Instrument:
  • Type of Instrument: Ordinary Shares of US$0.25 each in AstraZeneca PLC.
  • Identification Code: GB0009895292.
  1. Place of Transaction: The transaction took place on the London Stock Exchange (LON).
  2. Further Information: Additional details regarding the transaction adhere to the EU Market Abuse Regulation guidelines.
  3. Company Overview: AstraZeneca is described as a global biopharmaceutical company focusing on the discovery, development, and commercialization of medicines across various fields, including Oncology, Rare Diseases, and more.
  4. Signatory: The report is signed by Matthew Bowden, the Company Secretary, indicating official acknowledgment of the report's contents.

This summary highlights the essential information regarding the transaction conducted by a key executive of AstraZeneca, providing insights into the company's compliance with regulatory requirements and the specifics of the share sale.